Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

304P - Clinical profile and survival outcomes in Wilms tumor patient treated by SIOP protocol at a Regional cancer center

Date

07 Dec 2024

Session

Poster Display session

Presenters

Palugulla Kushala

Citation

Annals of Oncology (2024) 35 (suppl_4): S1505-S1530. 10.1016/annonc/annonc1689

Authors

P. Kushala1, R. Digumarti2, V. Toka3, K.C. Puligundla4, R. Parimkayala1, A. Padakanti1, S. Planjery1

Author affiliations

  • 1 Medical Oncology, MNJ Institute of Oncology & Regional Cancer Center, 500004 - Hyderabad/IN
  • 2 Medical Oncology, MNJ Institute of oncology and regional cancer centre, 500004 - Hyderabad/IN
  • 3 Medical Oncology Dept., Mnj institute of oncology & Regional Cancer Center, 500004 - Hyderabad/IN
  • 4 Medical Oncology Department, MNJ Institute of Oncology & Regional Cancer Center, 500004 - Hyderabad/IN

Resources

This content is available to ESMO members and event participants.

Abstract 304P

Background

Wilms tumour is the most common treatment responsive pediatric solid tumour. The outcome of Wilms tumour has improved due to the evolution of treatment approach. The purpose of this study was to analyse the clinical outcome of children with Wilms tumour treated by SIOP protocol in a regional cancer center.

Methods

In total 30 patients treated by SIOP protocol were analysed from a duration of June 2018 to June 2024.

Results

Gender distribution showed a male to female ratio of 6:1 with median age at diagnosis of 48 months with youngest being 7 months to oldest being 8 yrs . The abdominal lump was the dominant clinical presentation with a mean duration of 35 days (15 days to 2 months). Radiological staging work up showed that stages 1,2,3,4,5 were 23%,34%,13.3%, 40%,2 0%,3.3%, respectively. Neoadjuvant chemotherapy was received by all patients. In addition, 20% had metastasis at presentation, with lung as most common site and 46.4% of patients have high-risk histology. Disease relapse was seen in 20% of patients. Out of 24 alive patients 23 patients are without disease (15 months-69 months), one patient is alive with disease, and 6 patients died due to disease. The mean DFS and OS were 33.8 months (6months -69months) and 34.7 months (7 months -69 months), respectively.

Conclusions

The majority of patients presenting to our center are in advanced stage. Though the clinicopathological profile was more in line with western data,survival of patients with Wilms tumour is lower compared to high income countries due to delay in presentation and poor adherence to treatment.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

P. Kushala.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.